GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » EBITDA Margin %

Abcam (ABCZF) EBITDA Margin % : 26.72% (As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Abcam EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abcam's EBITDA for the six months ended in Jun. 2023 was $68.6 Mil. Abcam's Revenue for the six months ended in Jun. 2023 was $256.6 Mil. Therefore, Abcam's EBITDA margin for the quarter that ended in Jun. 2023 was 26.72%.


Abcam EBITDA Margin % Historical Data

The historical data trend for Abcam's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam EBITDA Margin % Chart

Abcam Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.57 37.86 27.74 15.81 11.81

Abcam Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Jun22 Dec22 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.49 9.85 18.79 4.48 26.72

Competitive Comparison of Abcam's EBITDA Margin %

For the Biotechnology subindustry, Abcam's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abcam's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abcam's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Abcam's EBITDA Margin % falls into.



Abcam EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Abcam's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=52.01/440.56
=11.81 %

Abcam's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=68.561/256.566
=26.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abcam  (OTCPK:ABCZF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Abcam EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Abcam's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abcam (ABCZF) Business Description

Traded in Other Exchanges
N/A
Address
Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX
Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.